fondaparinux 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
synthetic heparinoids	1236	104993-28-4

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: fondaparinux fondaparin heparin pentasaccharide fondaparinux sodium arixtra fondaparin sodium	Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery. Molecular weight: 1508.22 Formula: C31H53N3O49S8 CLOGP: -10.96 LIPINSKI: 3 HAC: 52 HDO: 19 TPSA: 805.48 ALOGS: -2.28 ROTB: 27

Molecule

Description

Molfile Inchi Smiles

Synonyms:

fondaparinux
fondaparin
heparin pentasaccharide
fondaparinux sodium
arixtra
fondaparin sodium

Synthetic pentasaccharide that mediates the interaction of HEPARIN with ANTITHROMBINS and inhibits FACTOR Xa; it is used for prevention of VENOUS THROMBOEMBOLISM after surgery.

Molecular weight: 1508.22
Formula: C31H53N3O49S8
CLOGP: -10.96
LIPINSKI: 3
HAC: 52
HDO: 19
TPSA: 805.48
ALOGS: -2.28
ROTB: 27

Drug dosage:

Dose	Unit	Route
2.50	mg	P

ADMET properties:

Property	Value	Reference
CL (Clearance)	0.07 mL/min/kg	Lombardo F, Berellini G, Obach RS
fu (Fraction unbound in plasma)	0.21 %	Lombardo F, Berellini G, Obach RS
t_half (Half-life)	19.30 hours	Lombardo F, Berellini G, Obach RS
S (Water solubility)	20 mg/mL	Bocci G, Oprea TI, Benet LZ
BDDCS (Biopharmaceutical Drug Disposition Classification System)	3	Bocci G, Oprea TI, Benet LZ
Vd (Volume of distribution)	0.14 L/kg	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
BA (Bioavailability)	1 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Approvals:

Date	Agency	Company	Orphan
Dec. 7, 2001	FDA	MYLAN IRELAND LTD

FDA Adverse Event Reporting System (Female)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	645.69	17.87	233	9896	34587	63444306
Muscle haemorrhage	356.33	17.87	86	10043	3093	63475800
Pulmonary embolism	276.14	17.87	192	9937	116492	63362401
Anaemia	233.12	17.87	259	9870	293171	63185722
Shock haemorrhagic	178.44	17.87	65	10064	9830	63469063
Cerebral haemorrhage	174.25	17.87	89	10040	30640	63448253
Heparin-induced thrombocytopenia	166.36	17.87	51	10078	4531	63474362
Incorrect product administration duration	165.11	17.87	64	10065	11482	63467411
Deep vein thrombosis	142.05	17.87	113	10016	83687	63395206
Haemorrhage	133.81	17.87	96	10033	60926	63417967
Post procedural haemorrhage	131.35	17.87	49	10080	7915	63470978
Haemoglobin decreased	124.75	17.87	134	9995	145351	63333542
Melaena	124.69	17.87	71	10058	30294	63448599
Intra-abdominal haematoma	123.81	17.87	33	10096	1772	63477121
Post procedural haematoma	119.83	17.87	30	10099	1255	63477638
Retroperitoneal haematoma	103.94	17.87	32	10097	2881	63476012
Subcutaneous haematoma	97.24	17.87	27	10102	1691	63477202
Subdural haematoma	94.47	17.87	46	10083	14282	63464611
Thrombocytopenia	84.49	17.87	112	10017	151045	63327848
Abdominal wall haematoma	81.91	17.87	27	10102	3028	63475865
Incision site haematoma	77.06	17.87	13	10116	67	63478826
Compartment syndrome	76.89	17.87	24	10105	2260	63476633
Haematemesis	76.30	17.87	52	10077	30360	63448533
Hypersensitivity myocarditis	76.19	17.87	15	10114	201	63478692
Thrombosis	66.88	17.87	66	10063	64689	63414204
Haemorrhage subcutaneous	66.70	17.87	23	10106	2960	63475933
Blood loss anaemia	65.72	17.87	31	10098	8970	63469923
Tooth erosion	54.02	17.87	13	10116	460	63478433
Extradural haematoma	53.42	17.87	17	10112	1705	63477188
Fatigue	52.89	17.87	39	10090	887989	62590904
Intra-abdominal haemorrhage	47.41	17.87	17	10112	2452	63476441
Incision site haemorrhage	46.38	17.87	12	10117	573	63478320
Thrombocytosis	42.35	17.87	20	10109	5798	63473095
Pulpitis dental	40.90	17.87	12	10117	916	63477977
Gastrointestinal haemorrhage	39.04	17.87	56	10073	81120	63397773
Hypovolaemic shock	38.04	17.87	19	10110	6222	63472671
Skin necrosis	35.32	17.87	24	10105	13926	63464967
Haemoperitoneum	34.97	17.87	14	10115	2727	63476166
Rectal haemorrhage	34.80	17.87	41	10088	48989	63429904
Toxic skin eruption	34.62	17.87	23	10106	12862	63466031
Cerebral haematoma	34.20	17.87	15	10114	3668	63475225
Abdominal wall haemorrhage	32.24	17.87	7	10122	155	63478738
Renal failure	32.15	17.87	63	10066	117589	63361304
Intraventricular haemorrhage	31.17	17.87	12	10117	2108	63476785
Oesophageal candidiasis	30.90	17.87	16	10113	5647	63473246
Red blood cell count decreased	30.53	17.87	35	10094	40610	63438283
Abdominal discomfort	30.36	17.87	7	10122	320878	63158015
Shock	30.12	17.87	27	10102	23436	63455457
Periodontitis	29.21	17.87	13	10116	3290	63475603
Wound haemorrhage	29.18	17.87	12	10117	2504	63476389
Gastric haemorrhage	29.07	17.87	16	10113	6382	63472511
Splenic rupture	28.69	17.87	10	10119	1328	63477565
Drug intolerance	28.68	17.87	7	10122	308654	63170239
Injection site haematoma	28.08	17.87	16	10113	6816	63472077
Retroperitoneal haemorrhage	27.96	17.87	12	10117	2785	63476108
Drug interaction	27.79	17.87	90	10039	229041	63249852
Pain	27.17	17.87	48	10081	740580	62738313
Venous thrombosis limb	27.12	17.87	12	10117	2996	63475897
Hepatic infarction	26.52	17.87	8	10121	672	63478221
Haematocrit decreased	26.44	17.87	32	10097	39308	63439585
Headache	26.07	17.87	38	10091	633203	62845690
Hemiplegia	25.92	17.87	17	10112	9306	63469587
Contraindicated product administered	24.43	17.87	3	10126	217645	63261248
Abdominal pain	24.40	17.87	102	10027	293354	63185539
Hypoperfusion	24.08	17.87	9	10120	1458	63477435
Drug hypersensitivity	23.64	17.87	10	10119	310677	63168216
Postoperative wound complication	23.57	17.87	8	10121	981	63477912
Spinal cord compression	23.44	17.87	12	10117	4136	63474757
Hepatic function abnormal	23.00	17.87	29	10100	37113	63441780
Prothrombin level decreased	22.97	17.87	7	10122	608	63478285
Drug ineffective	22.78	17.87	88	10041	1044677	62434216
Weight increased	22.19	17.87	7	10122	260785	63218108
Haemoptysis	22.02	17.87	25	10104	28701	63450192
Platelet count increased	21.98	17.87	20	10109	17691	63461202
Post procedural swelling	21.95	17.87	6	10123	354	63478539
Procedural haemorrhage	21.93	17.87	10	10119	2678	63476215
Insomnia	21.79	17.87	4	10125	215248	63263645
Rash maculo-papular	21.52	17.87	26	10103	31870	63447023
Sinusitis	21.32	17.87	5	10124	226648	63252245
Joint swelling	21.26	17.87	13	10116	327653	63151240
Nephropathy toxic	20.94	17.87	15	10114	9464	63469429
Spontaneous haematoma	20.41	17.87	7	10122	886	63478007
Traumatic haematoma	20.40	17.87	8	10121	1477	63477416
Haematuria	20.05	17.87	24	10105	29133	63449760
Breast haematoma	19.92	17.87	5	10124	211	63478682
Vulvovaginal injury	19.79	17.87	6	10123	512	63478381
Pelvic venous thrombosis	19.10	17.87	8	10121	1747	63477146
Haemodynamic instability	19.06	17.87	14	10115	9176	63469717
Brain herniation	18.95	17.87	10	10119	3667	63475226
Gastric ulcer haemorrhage	18.86	17.87	11	10118	4897	63473996
Arthralgia	18.19	17.87	40	10089	569670	62909223
Nasopharyngitis	18.06	17.87	9	10120	254248	63224645

FDA Adverse Event Reporting System (Male)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	211.27	18.90	102	6725	25503	34924601
Incorrect product administration duration	194.77	18.90	61	6766	4750	34945354
Muscle haemorrhage	133.35	18.90	43	6784	3675	34946429
Heparin-induced thrombocytopenia	119.83	18.90	44	6783	5551	34944553
Cerebral haemorrhage	100.09	18.90	70	6757	34867	34915237
Pulmonary embolism	99.27	18.90	104	6723	89642	34860462
Anaemia	96.56	18.90	167	6660	233168	34716936
Haemorrhage	94.41	18.90	79	6748	51291	34898813
Shock haemorrhagic	86.83	18.90	43	6784	11311	34938793
Post procedural haemorrhage	68.18	18.90	33	6794	8256	34941848
Haematoma muscle	62.32	18.90	19	6808	1349	34948755
Ureteric compression	58.19	18.90	13	6814	267	34949837
Post procedural haematoma	56.14	18.90	18	6809	1508	34948596
Subdural haematoma	54.01	18.90	39	6788	20382	34929722
Melaena	52.07	18.90	48	6779	35332	34914772
Deep vein thrombosis	47.44	18.90	61	6766	65187	34884917
Haematuria	44.81	18.90	52	6775	50014	34900090
Thrombocytosis	41.94	18.90	19	6808	4093	34946011
Haematemesis	41.55	18.90	38	6789	27673	34922431
Thrombocytopenia	40.32	18.90	92	6735	156155	34793949
Pyelocaliectasis	40.22	18.90	13	6814	1117	34948987
Extradural haematoma	39.57	18.90	13	6814	1176	34948928
Thrombosis	39.56	18.90	49	6778	50409	34899695
Retroperitoneal haematoma	35.88	18.90	15	6812	2663	34947441
Retroperitoneal haemorrhage	34.79	18.90	15	6812	2873	34947231
Intra-abdominal haematoma	33.92	18.90	12	6815	1358	34948746
Adrenal haemorrhage	33.68	18.90	8	6819	217	34949887
Gastrointestinal haemorrhage	33.36	18.90	61	6766	88416	34861688
Haemoglobin decreased	33.24	18.90	73	6754	120699	34829405
Spinal cord haemorrhage	30.57	18.90	8	6819	325	34949779
Abdominal wall haematoma	30.49	18.90	12	6815	1825	34948279
Venous thrombosis	26.22	18.90	13	6814	3422	34946682
Altered state of consciousness	26.06	18.90	27	6800	22866	34927238
Haemorrhage intracranial	24.15	18.90	22	6805	15924	34934180
Lumbosacral plexus injury	23.54	18.90	4	6823	17	34950087
Haemorrhagic stroke	23.24	18.90	15	6812	6524	34943580
Cerebral haematoma	22.61	18.90	13	6814	4602	34945502
Subacute cutaneous lupus erythematosus	21.89	18.90	8	6819	994	34949110
Intra-abdominal haemorrhage	21.06	18.90	10	6817	2394	34947710
Haemarthrosis	20.99	18.90	11	6816	3248	34946856
Haemothorax	19.27	18.90	11	6816	3841	34946263
Gastric haemorrhage	19.26	18.90	16	6811	10245	34939859
Purpura	19.19	18.90	16	6811	10295	34939809
Coma	19.13	18.90	33	6794	45645	34904459

FDA Adverse Event Reporting System (Geriatric)

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Haematoma	639.40	18.13	260	12773	51935	79679420
Muscle haemorrhage	300.31	18.13	87	12946	6213	79725142
Pulmonary embolism	292.05	18.13	234	12799	171420	79559935
Heparin-induced thrombocytopenia	255.47	18.13	85	12948	9597	79721758
Cerebral haemorrhage	245.13	18.13	139	12894	57534	79673821
Anaemia	230.71	18.13	321	12712	444694	79286661
Incorrect product administration duration	218.73	18.13	80	12953	11942	79719413
Shock haemorrhagic	191.98	18.13	84	12949	19976	79711379
Haemorrhage	162.74	18.13	128	12905	90990	79640365
Deep vein thrombosis	156.39	18.13	141	12892	120778	79610577
Post procedural haemorrhage	129.69	18.13	57	12976	13687	79717668
Post procedural haematoma	122.03	18.13	35	12998	2407	79728948
Melaena	120.60	18.13	91	12942	60799	79670556
Haematemesis	101.03	18.13	77	12956	52187	79679168
Intra-abdominal haematoma	99.20	18.13	31	13002	2860	79728495
Subdural haematoma	95.19	18.13	61	12972	31373	79699982
Thrombosis	93.09	18.13	90	12943	84010	79647345
Thrombocytopenia	90.19	18.13	158	12875	265101	79466254
Retroperitoneal haematoma	84.42	18.13	32	13001	5265	79726090
Subcutaneous haematoma	79.73	18.13	26	13007	2751	79728604
Abdominal wall haematoma	79.69	18.13	30	13003	4843	79726512
Haemoglobin decreased	78.99	18.13	135	12898	221984	79509371
Extradural haematoma	74.84	18.13	25	13008	2851	79728504
Hypersensitivity myocarditis	72.60	18.13	15	13018	253	79731102
Haematoma muscle	69.12	18.13	23	13010	2592	79728763
Blood loss anaemia	64.80	18.13	37	12996	15461	79715894
Thrombocytosis	63.51	18.13	30	13003	8496	79722859
Haematuria	60.37	18.13	65	12968	68771	79662584
Ureteric compression	60.35	18.13	13	13020	270	79731085
Pyelocaliectasis	53.99	18.13	15	13018	918	79730437
Incision site haemorrhage	51.74	18.13	15	13018	1071	79730284
Tooth erosion	50.39	18.13	12	13021	396	79730959
Compartment syndrome	47.68	18.13	21	13012	5061	79726294
Gastrointestinal haemorrhage	42.54	18.13	82	12951	147637	79583718
Fatigue	41.42	18.13	55	12978	929672	78801683
Adrenal haemorrhage	40.67	18.13	11	13022	609	79730746
Drug interaction	40.36	18.13	154	12879	415029	79316326
Skin necrosis	40.20	18.13	29	13004	18058	79713297
Brain herniation	40.00	18.13	21	13012	7442	79723913
Retroperitoneal haemorrhage	39.98	18.13	19	13014	5451	79725904
Haemorrhage subcutaneous	39.16	18.13	18	13015	4791	79726564
Toxicity to various agents	37.84	18.13	11	13022	421529	79309826
Gastric haemorrhage	37.79	18.13	26	13007	15024	79716331
Spinal cord haemorrhage	36.79	18.13	10	13023	564	79730791
Pulpitis dental	36.51	18.13	12	13021	1301	79730054
Injection site haematoma	36.00	18.13	17	13016	4810	79726545
Wound haemorrhage	35.22	18.13	16	13017	4145	79727210
Altered state of consciousness	34.30	18.13	39	12994	43783	79687572
Toxic skin eruption	32.77	18.13	28	13005	22265	79709090
Haemorrhage intracranial	32.72	18.13	30	13003	26163	79705192
Hypovolaemic shock	32.71	18.13	22	13011	12254	79719101
Incision site haematoma	32.42	18.13	7	13026	147	79731208
Rectal haemorrhage	31.96	18.13	50	12983	76250	79655105
Haemothorax	31.04	18.13	16	13017	5462	79725893
Nasopharyngitis	30.67	18.13	3	13030	253878	79477477
Drug intolerance	29.71	18.13	4	13029	264115	79467240
Off label use	28.75	18.13	249	12784	906966	78824389
Haemoperitoneum	28.46	18.13	14	13019	4329	79727026
Weight increased	27.26	18.13	6	13027	277380	79453975
Coma	26.69	18.13	54	12979	100595	79630760
Oesophageal candidiasis	25.71	18.13	17	13016	9201	79722154
Eosinophilia	25.23	18.13	34	12999	45311	79686044
Haemorrhagic stroke	25.21	18.13	18	13015	11028	79720327
Venous thrombosis limb	25.20	18.13	13	13020	4444	79726911
Venous thrombosis	24.53	18.13	15	13018	7101	79724254
Lumbosacral plexus injury	24.25	18.13	4	13029	17	79731338
Acute coronary syndrome	24.08	18.13	23	13010	21110	79710245
Hepatic infarction	23.99	18.13	8	13025	907	79730448
Pain	22.70	18.13	51	12982	703751	79027604
Rash maculo-papular	22.45	18.13	36	12997	56042	79675313
Periodontitis	22.26	18.13	12	13021	4484	79726871
Haemarthrosis	21.97	18.13	13	13020	5799	79725556
Abdominal discomfort	21.65	18.13	7	13026	250720	79480635
Drug hypersensitivity	21.51	18.13	11	13022	298905	79432450
Cross sensitivity reaction	21.49	18.13	11	13022	3701	79727654
Abdominal pain	21.14	18.13	122	12911	389447	79341908
Haemoptysis	21.13	18.13	35	12998	55964	79675391
Spinal cord compression	20.85	18.13	13	13020	6364	79724991
Cough	20.36	18.13	18	13015	366771	79364584
Postoperative wound complication	20.06	18.13	8	13025	1506	79729849
Upper gastrointestinal haemorrhage	20.00	18.13	29	13004	41351	79690004
Haemodynamic instability	19.96	18.13	19	13014	17363	79713992
Electrocardiogram QT prolonged	19.93	18.13	45	12988	90341	79641014
Product dose omission issue	19.53	18.13	8	13025	247529	79483826
Intra-abdominal haemorrhage	19.41	18.13	11	13022	4529	79726826
Brain stem haemorrhage	19.39	18.13	8	13025	1642	79729713
Insomnia	19.22	18.13	8	13025	245162	79486193
Procedural haemorrhage	19.04	18.13	11	13022	4695	79726660
Renal failure	19.02	18.13	74	12959	200894	79530461
Gastric ulcer haemorrhage	18.98	18.13	14	13019	9013	79722342
Infusion related reaction	18.89	18.13	7	13026	230230	79501125
Hypoperfusion	18.78	18.13	9	13024	2630	79728725
Intraventricular haemorrhage	18.65	18.13	11	13022	4876	79726479
Hemiplegia	18.44	18.13	17	13016	14922	79716433
Cerebellar haematoma	18.44	18.13	6	13027	630	79730725
Vulvovaginal injury	18.36	18.13	5	13028	284	79731071
Necrosis	18.36	18.13	14	13019	9479	79721876
Cerebral haematoma	18.26	18.13	13	13020	7929	79723426
Ecchymosis	18.18	18.13	17	13016	15189	79716166

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Source	Code	Description
ATC	B01AX05	BLOOD AND BLOOD FORMING ORGANS ANTITHROMBOTIC AGENTS ANTITHROMBOTIC AGENTS Other antithrombotic agents
MeSH PA	D000925	Anticoagulants
MeSH PA	D000991	Antithrombins
MeSH PA	D004791	Enzyme Inhibitors
MeSH PA	D065427	Factor Xa Inhibitors
MeSH PA	D006401	Hematologic Agents
MeSH PA	D011480	Protease Inhibitors
MeSH PA	D015842	Serine Proteinase Inhibitors
FDA MoA	N0000175635	Factor Xa Inhibitors
FDA EPC	N0000175637	Factor Xa Inhibitor
CHEBI has role	CHEBI:50249	anticoagulants

Drug Use | Suggest Off label Use Form| |View source of the data|

Disease	Relation	SNOMED_ID	DOID
Deep venous thrombosis	indication	128053003
Pulmonary thromboembolism	indication	233935004
Prevention of deep vein thrombosis	indication	439993001
Myocardial infarction	off-label use	22298006	DOID:5844
Acute coronary syndrome	off-label use	394659003
Diabetic retinopathy	contraindication	4855003	DOID:8947
Gastrointestinal ulcer	contraindication	40845000
Acute nephropathy	contraindication	58574008
Blood coagulation disorder	contraindication	64779008	DOID:1247
Operation on brain	contraindication	70586009
Heparin-induced thrombocytopenia	contraindication	73397007
Kidney disease	contraindication	90708001	DOID:557
Autoimmune thrombocytopenia	contraindication	128091003
Hemorrhagic cerebral infarction	contraindication	230706003
Local anesthetic intrathecal block	contraindication	231249005
Procedure on spine	contraindication	238181003
Anemia	contraindication	271737000	DOID:2355
Lumbar puncture	contraindication	277762005
Bacterial endocarditis	contraindication	301183007
Thrombocytopenic disorder	contraindication	302215000	DOID:1588
Surgical procedure on eye proper	contraindication	373353005
Hypertensive urgency	contraindication	443482000
Significant Bleeding	contraindication
Platelet Aggregation Inhibition	contraindication
Placement of Epidural Catheter	contraindication

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	0.23	acidic
pKa2	0.94	acidic
pKa3	2.46	acidic
pKa4	3.08	acidic
pKa5	11.49	acidic
pKa6	11.98	acidic
pKa7	12.26	acidic
pKa8	12.43	acidic
pKa9	12.91	acidic
pKa10	13.69	acidic

Orange Book patent data (new drug applications)

None

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Mechanism action	Bioact source	MoA source
Antithrombin-III	Secreted	P01008	ANT3_HUMAN	ACTIVATOR	Kd	7.49		IUPHAR	CHEMBL
Coagulation factor X	Enzyme	P00742	FA10_HUMAN		IC50	7		CHEMBL

External reference:

ID	Source
4021296	VUID
N0000148733	NUI
D01844	KEGG_DRUG
114870-03-0	SECONDARY_CAS_RN
4021296	VANDF
C1098510	UMLSCUI
CHEBI:61033	CHEBI
NTO	PDB_CHEM_ID
CHEMBL1201202	ChEMBL_ID
CHEMBL1276258	ChEMBL_ID
CHEMBL1200644	ChEMBL_ID
D000077425	MESH_DESCRIPTOR_UI
DB00569	DRUGBANK_ID
C049714	MESH_SUPPLEMENTAL_RECORD_UI
6819	IUPHAR_LIGAND_ID
J177FOW5JL	UNII
5282448	PUBCHEM_CID
321208	RXNORM
16268	MMSL
184641	MMSL
18938	MMSL
42652	MMSL
d04786	MMSL
009549	NDDF
009550	NDDF
385517000	SNOMEDCT_US
395236007	SNOMEDCT_US
708189008	SNOMEDCT_US
7653	INN_ID

Pharmaceutical products:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3443	INJECTION	2.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3454	INJECTION	5 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3465	INJECTION	7.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	0781-3476	INJECTION	10 mg	SUBCUTANEOUS	ANDA	27 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-154	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-155	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-156	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	ANDA	28 sections
fondaparinux sodium	HUMAN PRESCRIPTION DRUG LABEL	1	11797-157	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	ANDA	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-606	INJECTION	10 mg	SUBCUTANEOUS	ANDA	26 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-606	INJECTION	10 mg	SUBCUTANEOUS	ANDA	26 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-607	INJECTION	2.50 mg	SUBCUTANEOUS	ANDA	26 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-607	INJECTION	2.50 mg	SUBCUTANEOUS	ANDA	26 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-608	INJECTION	5 mg	SUBCUTANEOUS	ANDA	26 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-608	INJECTION	5 mg	SUBCUTANEOUS	ANDA	26 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-609	INJECTION	7.50 mg	SUBCUTANEOUS	ANDA	26 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	43598-609	INJECTION	7.50 mg	SUBCUTANEOUS	ANDA	26 sections
ARIXTRA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5501	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	NDA	27 sections
ARIXTRA	HUMAN PRESCRIPTION DRUG LABEL	1	54868-5652	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	NDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-678	INJECTION	2.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-679	INJECTION	5 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-680	INJECTION	7.50 mg	SUBCUTANEOUS	ANDA	27 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	55111-681	INJECTION	10 mg	SUBCUTANEOUS	ANDA	27 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-230	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	ANDA	28 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-231	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	ANDA	28 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-232	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	ANDA	28 sections
FONDAPARINUX SODIUM	Human Prescription Drug Label	1	55150-233	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	ANDA	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-582	INJECTION, SOLUTION	2.50 mg	SUBCUTANEOUS	NDA authorized generic	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-583	INJECTION, SOLUTION	5 mg	SUBCUTANEOUS	NDA authorized generic	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-584	INJECTION, SOLUTION	7.50 mg	SUBCUTANEOUS	NDA authorized generic	28 sections
Fondaparinux Sodium	HUMAN PRESCRIPTION DRUG LABEL	1	67457-585	INJECTION, SOLUTION	10 mg	SUBCUTANEOUS	NDA authorized generic	28 sections